Validation of Customized Cancer Panel for Detecting Somatic Mutations and Copy Number Alterations.
- Author:
Su Hye CHOI
1
;
Seung Hyun JUNG
;
Yeun Jun CHUNG
Author Information
- Publication Type:Original Article
- Keywords: cancer panel; high-throughput DNA sequencing; next-generation sequencing; precision medicine
- MeSH: DNA; Gene Frequency; High-Throughput Nucleotide Sequencing; Limit of Detection; Polymerase Chain Reaction; Precision Medicine
- From:Genomics & Informatics 2017;15(4):136-141
- CountryRepublic of Korea
- Language:English
- Abstract: Accurate detection of genomic alterations, especially druggable hotspot mutations in tumors, has become an essential part of precision medicine. With targeted sequencing, we can obtain deeper coverage of reads and handle data more easily with a relatively lower cost and less time than whole-exome or whole-genome sequencing. Recently, we designed a customized gene panel for targeted sequencing of major solid cancers. In this study, we aimed to validate its performance. The cancer panel targets 95 cancer-related genes. In terms of the limit of detection, more than 86% of target mutations with a mutant allele frequency (MAF) <1% can be identified, and any mutation with >3% MAF can be detected. When we applied this system for the analysis of Acrometrix Oncology Hotspot Control DNA, which contains more than 500 COSMIC mutations across 53 genes, 99% of the expected mutations were robustly detected. We also confirmed the high reproducibility of the detection of mutations in multiple independent analyses. When we explored copy number alterations (CNAs), the expected CNAs were successfully detected, and this result was confirmed by target-specific genomic quantitative polymerase chain reaction. Taken together, these results support the reliability and accuracy of our cancer panel in detecting mutations. This panel could be useful for key mutation profiling research in solid tumors and clinical translation.
